Literature DB >> 2891127

Somatostatin analogue SMS 201-995 long term therapy for vipoma.

L D Juby1, D A Burke, A T Axon.   

Abstract

The definitive treatment of a pancreatic tumour secreting vasoactive intestinal polypeptide is surgical removal of the tumour, but when curative resection is not possible symptomatic treatment of the endocrine hyperfunction is important. Streptozotocin, although effective for palliation, can involve unpleasant side effects. We report the long term use of subcutaneous somatostatin analogue SMS 201-995 in an elderly man presenting with severe watery diarrhoea and anaemia due to a pancreatic vipoma. Good symptomatic improvement has been achieved with no side effects over a period of 24 months. We suggest there is a use for subcutaneous SMS 201-995 in elderly patients with inoperable pancreatic gut hormone producing tumours with metastases and in those where surgery would carry a high operative risk.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891127      PMCID: PMC2428160          DOI: 10.1136/pgmj.63.738.287

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  12 in total

Review 1.  Somatostatin. Physiology and clinical applications.

Authors:  J E Gerich; G S Patton
Journal:  Med Clin North Am       Date:  1978-03       Impact factor: 5.456

2.  [Preliminary observations on the mechanism of action of somatostatin, a hypothalamic factor inhibiting the secretion of growth hormone].

Authors:  W Vale; P Brazeau; G Grant; A Nussey; R Burgus; J Rivier; N Ling; R Guillemin
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1972-12-18

3.  Can inhibition of hormone secretion be associated with endocrine tumour shrinkage?

Authors:  M E Kraenzlin; J C Ch'ng; S M Wood; S R Bloom
Journal:  Lancet       Date:  1983 Dec 24-31       Impact factor: 79.321

4.  Regression of metastatic vipoma with somatostatin analogue SMS 201-995.

Authors:  D Clements; E Elias
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

5.  Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.

Authors:  M E Kraenzlin; J L Ch'ng; S M Wood; D H Carr; S R Bloom
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

6.  Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

Authors:  S M Wood; M E Kraenzlin; T E Adrian; S R Bloom
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

7.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; J A Hanley; L A Johnson
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

8.  Somatostatin inhibits diarrhea in the carcinoid syndrome.

Authors:  K Dharmsathaphorn; R S Sherwin; S Cataland; B Jaffe; J Dobbins
Journal:  Ann Intern Med       Date:  1980-01       Impact factor: 25.391

9.  Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water, and electrolytes.

Authors:  G J Krejs; R Browne; P Raskin
Journal:  Gastroenterology       Date:  1980-01       Impact factor: 22.682

10.  Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue.

Authors:  R G Long; A J Barnes; T E Adrian; C N Mallinson; M R Brown; W Vale; J E Rivier; N D Christofides; S R Bloom
Journal:  Lancet       Date:  1979-10-13       Impact factor: 79.321

View more
  4 in total

Review 1.  Somatostatin and analogues in the treatment of cancer. A review.

Authors:  B M Evers; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

2.  Effect of somatostatin analog (SMS 201-995) on in vivo intestinal fluid transport in rats. A limited systemic effect.

Authors:  R N Fedorak; S L Allen
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

Review 3.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

4.  Prevalence of Diagnostic Methods and Treatment Modalities in Vipoma Patients: A Rare Cause of Hormone-Mediated Diarrhea.

Authors:  Fateme Shamekhi Amiri
Journal:  Indian J Endocrinol Metab       Date:  2019 May-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.